Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Arugula Sciences General Information
Received FDA approval for Phase 1 clinical trials for two products: SIG001 (Signature Cord Prime™) for knee osteoarthritis and SIG002 (perinatal-derived secretome product) for big toe osteoarthritis. First participant for SIG002 was expected to be enrolled in February 2023.
Contact Information
Primary Industry
Biotech
Corporate Office
Irving, Texas
United States
United States
Drug Pipeline
Signature Cord Prime
Phase 1Key Partnerships
Forte Orthopedic Research Institute
Arugula Sciences Funding
No funding data available
To view Arugula Sciences's complete valuation and funding history, request access »